Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 3/20 | 0.52 |
| ▸ | CNR2 | P34972 | 10/20 | 0.50 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3095085 | 0.87 | CNR2 (0.52) | CNR1CNR2 | |
| SCHEMBL3083041 | 0.84 | KDM4E (0.56) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL29838956 | 0.82 | CNR2 (0.71) | CNR1CNR2 | |
| SCHEMBL923180 | 0.82 | CNR2 (0.71) | CNR1CNR2 | |
| SCHEMBL12907707 | 0.81 | CNR1 (0.66) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL24225739 | 0.80 | KDM4E (0.68) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL13955262 | 0.80 | KDM4E (0.68) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL662250 | 0.80 | CNR1 (0.65) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL4612450 | 0.80 | CNR1 (0.67) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL2627954 | 0.79 | CNR1 (0.68) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803799-B2 | such as 1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-5-(selenophen-2-yl)-1H-pyrazole-3-carboxamide, used for treating cannabinoid-receptor mediated disorders selected from obesity, metabolic syndrome, drug abuse and dependence or neuropathic pain | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-09-28 | — | — | US | disclosed |
| US-7705024-B2 | Oxadiazole compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-04-27 | — | — | US | disclosed |
| US-20080255211-A1 | Oxadiazole Compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-10-16 | — | — | US | disclosed |
| US-20080021031-A1 | SELENOPHENE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021031-A1 | SELENOPHENE COMPOUNDS | CNR2, CNR1, SELENOI | KDM4E 1250/4885MEN1 1271/4885MAPT 595/4885 |
| US-20080255211-A1 | Oxadiazole Compounds | CNR1, CNR2, OPRD1 | KDM4E 2511/4885MEN1 3156/4885MAPT 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.